Micardis-based regimens help achieve patient blood pressure goals

Germany's Boehringer Ingelheim says that results of two new studies of Micardis (telmisartan) in free combination with amlodipine or fixed combination with hydrochlorothiazide 25mg confirm that a telmisartan-based approach to treating hypertensive patients at risk of cardiovascular events can provide powerful and sustained blood pressure control in a broad range of people, including those who are difficult to treat. The study results were presented at the 18th annual meeting of the European Society of Hypertension and of the International Society of Hypertension, held in Berlin, Germany. In a study combining telmisartan, a modern angiotensin II receptor blocker, and amlodipine, the most widely-used calcium channel blocker, after eight weeks, significant blood pressure reductions were observed for all combinations of clinical interest (telmisartan 40mg or 80mg plus amlodipine 5mg or 10mg; p<0.05), the firm noted.